Previous 10 | Next 10 |
ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 ...
2023-03-14 07:09:16 ET AxoGen press release ( NASDAQ: AXGN ): Q4 Non-GAAP EPS of -$0.03 beats by $0.08 . Revenue of $36.2M (+14.8% Y/Y) in-line. 2023Guidance: Management expects full-year 2023 revenue to be in the range of $154 million to $159 million vs consen...
ALACHUA, Fla. and TAMPA, Fla., March 14, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the fourth quarter and full year end...
2023-03-13 13:53:03 ET AxoGen ( NASDAQ: AXGN ) is scheduled to announce Q4 earnings results on Tuesday, March 14th, before market open. The consensus EPS Estimate is -$0.11 (-37.5% Y/Y) and the consensus Revenue Estimate is $36.2M (+14.8% Y/Y). Over the last 2 years, A...
2023-03-13 11:09:59 ET Major earning expected before the bell on Tuesday include: Agenus ( AGEN ) Blade Air Mobility ( BLDE ) Kopin ( KOPN ) McEwen Mining ( MUX ) Volkswagen AG ( OTCPK:VWAGY ) For further details see: Notable earnings befo...
2023-03-06 14:26:13 ET Summary AxoGen's revenue tracked a little ahead of expectations in FY'22, and the company has recently seen some momentum with surgeons increasing their usage of the company's grafts. Between the RECON results and a recent meta-analysis of past studies, the ...
ALACHUA, Fla. and TAMPA, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report fourth quarter 2022 financial results on Tuesday, March 14, 2...
ALACHUA, Fla. and TAMPA, Fla., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Jens Schroeder Kemp to the newly created role of Chief Marketin...
ALACHUA, Fla. and TAMPA, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced preliminary unaudited fourth quarter and full-year 2022 revenue. Prelimina...
ALACHUA, Fla. and TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the independent publication of a comprehensive, retrospective clinical review comp...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...